Repatha vs Amlodipine: Cost and Access Head-to-Head

Why These Two Drugs Get Compared

Repatha and amlodipine both appear on cardiometabolic formularies, but they do entirely different jobs. Patients searching for one against the other are typically trying to understand which medication their insurer will cover more readily, or whether the expensive injectable is worth it when a cheap daily pill exists.

The comparison reflects a real clinical question that arises when a patient with atherosclerotic cardiovascular disease (ASCVD) also has hypertension. Their physician may prescribe amlodipine for blood pressure and consider adding Repatha for residual LDL-C risk. These are not interchangeable therapies. Amlodipine belongs to the dihydropyridine calcium channel blocker class, relaxing vascular smooth muscle to lower blood pressure 1. Evolocumab is a monoclonal antibody that binds PCSK9 protein, preventing degradation of hepatic LDL receptors and producing LDL-C reductions of approximately 59% on top of statin therapy 2. A patient might need both, but rarely would one replace the other. The cost gap between them, however, forces a practical access conversation that affects treatment decisions every day.

Mechanism and Indication Differences

Evolocumab blocks PCSK9 to increase LDL receptor recycling at the liver surface, pulling more LDL particles from circulation. Amlodipine inhibits L-type calcium channels in arterial smooth muscle, reducing peripheral vascular resistance and lowering blood pressure.

The FDA approved Repatha in 2015 for three indications: adults with established ASCVD needing additional LDL lowering, adults with heterozygous familial hypercholesterolemia (HeFH), and patients aged 10 years or older with homozygous familial hypercholesterolemia (HoFH) 3. Amlodipine, first approved in 1992, carries indications for hypertension and chronic stable or vasospastic angina 4. The 2018 AHA/ACC cholesterol guideline positions PCSK9 inhibitors as add-on therapy for very high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe 5. Amlodipine appears in the 2017 ACC/AHA hypertension guideline as a first-line option for stage 1 or stage 2 hypertension 6. No guideline recommends choosing one of these agents over the other because their targets are distinct.

Head-to-Head Trial Data: What Exists and What Does Not

No randomized controlled trial has directly compared evolocumab against amlodipine. This matters. Any "head-to-head" framing between these drugs is synthetic, drawn from separate trials with different populations, endpoints, and follow-up periods.

The FOURIER trial enrolled 27,564 patients with established ASCVD already receiving statin therapy. Over a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% relative to placebo (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) 2. The absolute risk reduction was 1.5 percentage points, translating to a number needed to treat (NNT) of 67 over 2.2 years.

ASCOT-BPLA randomized 19,257 hypertensive patients with at least three additional cardiovascular risk factors to an amlodipine-based or atenolol-based regimen. The trial was stopped early at 5.5 years of median follow-up because the amlodipine arm showed fewer total cardiovascular events and procedures (HR 0.84 to 95% CI 0.78 to 0.90, P<0.0001) and lower all-cause mortality (HR 0.89 to 95% CI 0.81 to 0.99, P=0.025) 1.

Comparing these results side by side is tempting but misleading. FOURIER measured add-on LDL-lowering benefit; ASCOT-BPLA measured a blood pressure strategy comparison. The populations, background therapies, and risk profiles were different. The only honest conclusion: both drugs reduce cardiovascular events within their respective domains of action.

Cost Breakdown: List Price, Net Price, and Out-of-Pocket

The sticker-price gap between these two medications is enormous. Generic amlodipine 5 mg or 10 mg costs between $4 and $15 per month at most U.S. retail pharmacies, and several chains include it on $4 generic lists. Repatha carries a wholesale acquisition cost (WAC) of approximately $514 per monthly autoinjector, or about $6,168 per year.

That WAC figure does not tell the whole story. Amgen reduced Repatha's list price by about 60% in 2018 (from roughly $14,100 to about $5,850 annually), and further rebate negotiations have brought net prices lower for some payers 7. The Institute for Clinical and Economic Review (ICER) estimated that a cost-effective price for PCSK9 inhibitors at a $150,000-per-QALY threshold would fall between $2,300 and $3,400 per year, a target the current net price approaches but may not consistently meet across all payer contracts 8.

For commercially insured patients, Amgen's copay card program can reduce out-of-pocket costs to $5 per month for eligible individuals. Medicare Part D patients face a different situation: the copay card is not available to them, and depending on their plan's formulary tier, annual out-of-pocket spending on Repatha can reach $1,000 to $3,000 even after the Part D redesign under the Inflation Reduction Act, which capped total out-of-pocket prescription costs at $2,000 starting in 2025 9.

Generic amlodipine has no comparable access barriers. It sits on the lowest formulary tier for virtually every commercial and government plan. No prior authorization is required. No step therapy is mandated.

Insurance Coverage and Prior Authorization

Getting Repatha covered requires clearing multiple administrative hurdles that do not exist for amlodipine. Most commercial insurers and Medicare Part D plans place evolocumab on specialty tier (tier 4 or 5) and require prior authorization documentation showing the patient has tried and failed, or is intolerant to, maximally tolerated statin therapy plus ezetimibe.

Dr. Seth Baum, past president of the American Society for Preventive Cardiology, has noted: "The prior authorization burden for PCSK9 inhibitors remains one of the most significant barriers to guideline-directed lipid therapy in the United States." A 2019 analysis in JAMA Cardiology found that initial prior authorization rejection rates for PCSK9 inhibitors exceeded 50% across several major insurers, though approval rates improved on appeal 10.

Common documentation requirements for Repatha prior authorization include:

• Confirmed ASCVD diagnosis or familial hypercholesterolemia
• Current LDL-C level on maximally tolerated statin (with or without ezetimibe)
• Documentation of statin intolerance (if applicable), including specific statins tried and adverse effects experienced
• Prescribing physician attestation that the patient meets guideline criteria

Amlodipine, by contrast, is prescribed and dispensed with no utilization management in standard practice. The entire process from prescription to pickup typically takes hours, not the weeks-to-months timeline that Repatha prior authorization can involve.

Efficacy in Context: What Each Drug Actually Does

Comparing efficacy between a PCSK9 inhibitor and a calcium channel blocker requires understanding that they target different physiologic pathways contributing to cardiovascular disease.

Evolocumab's primary measurable effect is LDL-C reduction. In FOURIER, patients receiving evolocumab achieved a median LDL-C of 30 mg/dL, down from a baseline of 92 mg/dL, a 59% reduction 2. This LDL lowering translated into the 15% MACE reduction noted above. A post-hoc analysis of FOURIER showed that benefit increased with longer exposure: in the second year of treatment, the relative risk reduction for the key secondary endpoint (cardiovascular death, MI, or stroke) reached 25% 11.

Amlodipine's primary effect is blood pressure reduction. In ASCOT-BPLA, the amlodipine-based regimen produced mean blood pressure of 136.1/77.4 mmHg compared with 137.7/79.2 mmHg in the atenolol group, a modest difference that nonetheless associated with significant reductions in stroke (23%, P=0.0003), total cardiovascular events (16%, P<0.0001), and all-cause mortality (11%, P=0.025) 1.

For a patient with both uncontrolled hypertension and elevated LDL-C despite statin therapy, these drugs address independent risk factors. The 2019 ACC/AHA Primary Prevention Guideline explicitly recommends treating both blood pressure and lipids as separate but complementary interventions 12.

Safety and Tolerability Profiles

Both drugs have well-characterized safety data from large outcome trials and years of post-marketing surveillance.

Repatha's most common adverse effects are injection-site reactions (reported in approximately 3% to 5% of patients), nasopharyngitis, upper respiratory tract infection, and influenza-like symptoms. The FOURIER trial found no significant difference in serious adverse events between evolocumab and placebo groups, including no increase in neurocognitive events, new-onset diabetes, or myalgia 2. The EBBINGHAUS sub-study specifically evaluated cognitive function over a median of 19 months and found no difference between groups 13.

Amlodipine's most frequent side effect is peripheral edema, occurring in approximately 8% to 10% of patients on the 10 mg dose. Other common effects include dizziness, flushing, and headache. Serious adverse events are rare. The ALLHAT trial (N=33,357) confirmed long-term safety of amlodipine over 4.9 years of follow-up, with no excess heart failure compared to chlorthalidone when the complete follow-up period was analyzed 14.

From a tolerability standpoint, amlodipine wins on convenience: it is a once-daily oral tablet. Repatha requires subcutaneous injection every two weeks (140 mg) or once monthly (420 mg via three consecutive injections or the Pushtronex system). Needle aversion and injection-site discomfort contribute to discontinuation in some patients.

Who Should Get Which Drug

The clinical decision between these therapies is not "either/or" but rather "which risk factor needs treatment."

A patient with Stage 2 hypertension and normal LDL-C levels needs amlodipine (or another antihypertensive), not Repatha. A patient with established ASCVD, LDL-C of 85 mg/dL on rosuvastatin 40 mg plus ezetimibe, and blood pressure of 118/72 mmHg needs Repatha added, not amlodipine. Many high-risk patients need both.

The 2018 AHA/ACC Multisociety Cholesterol Guideline defines the "very high-risk" ASCVD subgroup as patients with a history of multiple major ASCVD events or one major ASCVD event plus multiple high-risk conditions 5. For these patients, if LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor like evolocumab is a class IIa recommendation (level of evidence A).

Dr. Robert Giugliano, FOURIER co-principal investigator and associate professor at Harvard Medical School, has stated: "The challenge is not whether PCSK9 inhibitors work. The challenge is getting them to the patients who need them most, and cost remains the dominant barrier."

Practical Access Strategies

For patients prescribed Repatha who face coverage barriers, several strategies can improve access:

Amgen's copay assistance program covers up to $14,000 annually for commercially insured patients, often reducing monthly cost to $5. For uninsured or Medicare patients, Amgen's patient assistance program provides free drug supply to those with household incomes below 300% of the federal poverty level.

Appeals processes matter. The 2019 JAMA Cardiology analysis showed that while initial PCSK9 inhibitor prior authorization denials exceeded 50%, appeal success rates reached approximately 60% to 80% when prescribers submitted complete clinical documentation including LDL-C values, statin trial history, and ASCVD event documentation 10.

For amlodipine, cost optimization is simpler. GoodRx and similar platforms show 30-day supplies at $3 to $8 without insurance. The Mark Cuban Cost Plus Drug Company offers amlodipine besylate 10 mg at $3.60 for a 30-day supply. Pill splitting (using a 10 mg tablet for a 5 mg dose) is pharmacologically acceptable with amlodipine since it is not an extended-release formulation.

Biosimilar and Generic Outlook

Amlodipine has been available as a generic since Norvasc's patent expired in 2007. Multiple manufacturers produce it, and price competition keeps costs low with no foreseeable change.

Repatha's patent situation is more complex. Amgen holds multiple patents on evolocumab, with key composition-of-matter and method-of-use patents extending into the late 2020s and early 2030s. No biosimilar application for evolocumab has been approved by the FDA as of May 2026. Inclisiran (Leqvio), a siRNA-based PCSK9 synthesis inhibitor given only twice yearly, represents an alternative mechanism rather than a true biosimilar, and carries its own access challenges with a list price of approximately $6,500 per year 15.

Patients hoping for a cheaper version of Repatha will likely wait several more years. For the foreseeable period, the cost disparity between these two classes of cardiovascular medications will persist, making formulary placement, copay programs, and prior authorization navigation the primary determinants of real-world access to PCSK9 inhibitor therapy.

Patients taking Repatha should confirm their copay assistance enrollment annually, as program terms change with each calendar year, and maintain documentation of their ASCVD history for re-authorization cycles that most insurers require every 6 to 12 months.